Biological Therapies in Children and Adolescents with Severe Uncontrolled Asthma: A Practical Review

References

• Sánchez-Borges M, Martin BL, Muraro AM, et al. The importance of allergic disease in public health: an iCAALL statement. World Allergy Organ J. 2018;11(1):8. doi:10.1186/s40413-018-0187-2
   PubMed Web of Science ®Google Scholar
• Licari A, Manti S, Marseglia A, et al. Biologics in children with allergic diseases. Curr Pediatr Rev. 2020;16(2):140–147. doi:10.2174/1573396315666191029123822
   PubMed Web of Science ®Google Scholar
• Licari A, Ciprandi R, Marseglia G, et al. Anxiety and depression in adolescents with severe asthma and in their parents: preliminary results after 1 year of treatment. Behav Sci (Basel). 2019;9(7):78. doi:10.3390/bs9070078
   PubMedGoogle Scholar
• Licari A, Ciprandi R, Marseglia G, et al. Anxiety and depression in adolescents with asthma and in their parents: a study in clinical practice. Monaldi Arch Chest Dis. 2019;89(3):3. doi:10.4081/monaldi.2019.1063
   Web of Science ®Google Scholar
• Licari A, Ciprandi R, Marseglia G, et al. Anxiety/depression changes are associated with improved asthma control perception in asthmatic adolescents after adequate management. Eur Ann Allergy Clin Immunol. 2019;51(4):190–192. doi:10.23822/EurAnnACI.1764-1489.97
   Web of Science ®Google Scholar
• Votto M, Castagnoli R, De Filippo M, et al. Behavioral issues and quality of life in children with eosinophilic esophagitis. Minerva Pediatr. 2020;72(5):424–432. doi:10.23736/S0026-4946.20.05913-7
   PubMed Web of Science ®Google Scholar
• Manka LA, Wechsler ME. New biologics for allergic diseases. Expert Rev Clin Immunol. 2018;14(4):285–296. doi:10.1080/1744666X.2018.1459188
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, Brambilla I, et al. Asthma endotyping and biomarkers in childhood asthma. Pediatr Allergy Immunol Pulmonol. 2018;31(2):44–55. doi:10.1089/ped.2018.0886
   PubMed Web of Science ®Google Scholar
• Rusconi F, Fernandes RM, Pijnenburg MWH, et al. The severe paediatric asthma collaborative in Europe (SPACE) ERS clinical research collaboration: enhancing participation of children with asthma in therapeutic trials of new biologics and receptor blockers. Eur Respir J. 2018;52(4):1801665. doi:10.1183/13993003.01665-2018
   Web of Science ®Google Scholar
• Montalbano L, Ferrante G, Montella S, et al. Relationship between quality of life and behavioural disorders in children with persistent asthma: a Multiple Indicators Multiple Causes (MIMIC) model. Sci Rep. 2020;10(1):6957. doi:10.1038/s41598-020-62264-9
   PubMed Web of Science ®Google Scholar
• Licari A, Brambilla I, Marseglia A, et al. Difficult vs. severe asthma: definition and limits of asthma control in the pediatric population. Front Pediatr. 2018;6:170. doi:10.3389/fped.2018.00170
   PubMed Web of Science ®Google Scholar
• Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1):1900588. doi:10.1183/13993003.00588-2019
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention [homepage on the Internet]. Available from: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf. Accessed February 22, 2021.
   Google Scholar
• BTS/SIGN British guideline on the management of asthma [homepage on the Internet]. Available from: https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/. Accessed February 22, 2021.
   Google Scholar
• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013
   PubMed Web of Science ®Google Scholar
• Miraglia Del Giudice M, Marseglia GL, Leonardi S, et al. Fractional exhaled nitric oxide measurements in rhinitis and asthma in children. Int J Immunopathol Pharmacol. 2011;24(4Suppl):29–32. doi:10.1177/03946320110240S407
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, Denicolò CF, et al. The nose and the lung: united airway disease? Front Pediatr. 2017;5:44. doi:10.3389/fped.2017.00044
   PubMed Web of Science ®Google Scholar
• Licari A, Brambilla I, De Filippo M, et al. The role of upper airway pathology as a comorbidity in severe asthma. Expert Rev Respir Med. 2017;11(11):855–865. doi:10.1080/17476348.2017.1381564
   PubMed Web of Science ®Google Scholar
• Fitzpatrick AM. Severe asthma in children: lessons learned and future directions. J Allergy Clin Immunol Pract. 2016;4(1):11–19. doi:10.1016/j.jaip.2015.10.008
   PubMed Web of Science ®Google Scholar
• Fleming L, Murray C, Bansal AT, et al. The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. Eur Respir J. 2015;46(5):1322–1333. doi:10.1183/13993003.00780-2015
   PubMed Web of Science ®Google Scholar
• Montella S, Baraldi E, Cazzato S, et al. Severe asthma features in children: a case-control online survey. Ital J Pediatr. 2016;42(1):9. doi:10.1186/s13052-016-0217-z
   PubMed Web of Science ®Google Scholar
• Ramratnam SK, Bacharier LB, Guilbert TW. Severe asthma in children. J Allergy Clin Immunol Pract. 2017;5(4):889–898. doi:10.1016/j.jaip.2017.04.031
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, Brambilla I, et al. New approaches for identifying and testing potential new anti-asthma agents. Expert Opin Drug Discov. 2018;13(1):51–63. doi:10.1080/17460441.2018.1396315
   PubMed Web of Science ®Google Scholar
• Robinson D, Humbert M, Buhl R, et al. Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47(2):161–175. doi:10.1111/cea.12880
   PubMed Web of Science ®Google Scholar
• Samitas K, Zervas E, Gaga M. T2-low asthma: current approach to diagnosis and therapy. Curr Opin Pulm Med. 2017;23(1):48–55. doi:10.1097/MCP.0000000000000342
   PubMed Web of Science ®Google Scholar
• Manti S, Brown P, Perez MK, et al. The role of neurotrophins in inflammation and allergy. Vitam Horm. 2017;104:313–341.
   PubMed Web of Science ®Google Scholar
• Licari A, Marseglia GL. Current and future challenges in pediatric severe asthma. Curr Med Res Opin. 2018;34(5):943–944. doi:10.1080/03007995.2018.1439463
   PubMed Web of Science ®Google Scholar
• Licari A, Manti S, Chiappini E, et al. Severe asthma in children: current goals and unmet needs. Pediatr Allergy Immunol. 2020;31(Suppl 24):40–42. doi:10.1111/pai.13168
   Web of Science ®Google Scholar
• Licari A, Marseglia G, Castagnoli R, et al. The discovery and development of omalizumab for the treatment of asthma. Expert Opin Drug Discov. 2015;10(9):1033–1042. doi:10.1517/17460441.2015.1048220
   PubMed Web of Science ®Google Scholar
• Licari A, Marseglia A, Caimmi S, et al. Omalizumab in children. Paediatr Drugs. 2014;16(6):491–502. doi:10.1007/s40272-014-0107-z
   PubMed Web of Science ®Google Scholar
• Chipps BE, Lanier B, Milgrom H, et al. Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. J Allergy Clin Immunol. 2017;139(5):1431–1444. doi:10.1016/j.jaci.2017.03.002
   PubMed Web of Science ®Google Scholar
• Sesé L, Schneider M, Bourgoin M, et al. Asthma with multiple allergic comorbidities is associated with complete response to omalizumab. Clin Exp Allergy. 2019;49(5):733. doi:10.1111/cea.13373
   PubMed Web of Science ®Google Scholar
• Sorkness CA, Wildfire JJ, Calatroni A, et al. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. J Allergy Clin Immunol Pract. 2013;1(2):163–171. doi:10.1016/j.jaip.2013.01.011
   PubMed Web of Science ®Google Scholar
• Licari A, Manti S, Castagnoli R, et al. Targeted therapy for severe asthma in children and adolescents: current and future perspectives. Paediatr Drugs. 2019;21(4):215–237. doi:10.1007/s40272-019-00345-7
   PubMed Web of Science ®Google Scholar
• Brodlie M, McKean MC, Moss S, et al. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch Dis Child. 2012;97(7):604–609. doi:10.1136/archdischild-2011-301570
   PubMed Web of Science ®Google Scholar
• Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005–1015. doi:10.1056/NEJMoa1009705
   PubMed Web of Science ®Google Scholar
• Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009;124(6):1210–1216. doi:10.1016/j.jaci.2009.09.021
   PubMed Web of Science ®Google Scholar
• Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol. 2015;136(6):1476–1485. doi:10.1016/j.jaci.2015.09.008
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Neffen H. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents. Pediatr Allergy Immunol. 2015;26(6):551–556. doi:10.1111/pai.12405
   PubMed Web of Science ®Google Scholar
• Deschildre A, Marguet C, Salleron J, et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J. 2013;42(5):1224–1233. doi:10.1183/09031936.00149812
   PubMed Web of Science ®Google Scholar
• Deschildre A, Marguet C, Langlois C, et al. Real-life long-term omalizumab therapy in children with severe allergic asthma. Eur Respir J. 2015;46(3):856–859. doi:10.1183/09031936.00008115
   PubMed Web of Science ®Google Scholar
• Licari A, Castagnoli R, Denicolo C, et al. Omalizumab in children with severe allergic asthma: the Italian real-life experience. Curr Respir Med Rev. 2017;13(1):36–42. doi:10.2174/1573398X13666170426094536
   PubMed Web of Science ®Google Scholar
• Pitrez PM, de Souza RG, Roncada C, et al. Impact of omalizumab in children from a middle-income country with severe therapy-resistant asthma: a Real-Life Study. Pediatr Pulmonol. 2017;52(11):1408–1413. doi:10.1002/ppul.23845
   PubMed Web of Science ®Google Scholar
• Berger W, Gupta N, McAlary M, et al. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol. 2003;91(2):182–188. doi:10.1016/S1081-1206(10)62175-8
   Web of Science ®Google Scholar
• Milgrom H, Fowler-Taylor A, Vidaurre CF, et al. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin. 2011;27(1):163–169. doi:10.1185/03007995.2010.539502
   PubMed Web of Science ®Google Scholar
• Busse W, Buhl R, Fernandez vidaurre C, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol. 2012;129(4):983–989. doi:10.1016/j.jaci.2012.01.033
   PubMed Web of Science ®Google Scholar
• Long A, Rahmaoui A, Rothman KJ, et al. Incidence of malignancy in patients with moderate-to- severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014;134(3):560–567. doi:10.1016/j.jaci.2014.02.007
   PubMed Web of Science ®Google Scholar
• Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1:CD003559.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Nucala® [homepage on the Internet]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/nucala. Accessed April 23, 2021.
   Google Scholar
• Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176(11):1062–1071. doi:10.1164/rccm.200701-085OC
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Nucala® [homepage on the Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761122s000lbl.pdf. Accessed February 22, 2021.
   Google Scholar
• GSK European Commission approves Nucala (mepolizumab) for the treatment of children with severe asthma. [homepage on the Internet]. Available from: https://www.gsk.com/en-gb/media/press-releases/european-commission-approves-nucala-mepolizumab-for-the-treatment-of-children-with-severe-asthma/. Accessed February 22, 2021.
   Google Scholar
• Kline GS. Nucala® (mepolizumab) prescribing information. [homepage on the Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125526Orig1s000Lbl.pdf. Accessed April 27, 2021.
   Google Scholar
• Drick N, Seeliger B, Welte T, et al. Anti-IL-5 therapy in patients with severe eosinophilic asthma-clinical efficacy and possible criteria for treatment response. BMC Pulm Med. 2018;18(1):119. doi:10.1186/s12890-018-0689-2
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197. doi:10.1056/NEJMoa1403291
   PubMed Web of Science ®Google Scholar
• Haldar P. Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma. Biologics. 2017;11:81–95. doi:10.2147/BTT.S93954
   PubMed Web of Science ®Google Scholar
• Mepolizumab for treating severe refractory eosinophilic asthma. NICE technology appraisal guidance [TA431] [homepage on the Internet]. Available from: https://www.nice.org.uk/guidance/ta431. Accessed February 22, 2021.
   Google Scholar
• Farne HA, Wilson A, Powell C, et al. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:CD010834. doi:10.1002/14651858.CD010834.pub3
   PubMed Web of Science ®Google Scholar
• Pavord ID, Kom S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi:10.1016/S0140-6736(12)60988-X
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290
   PubMed Web of Science ®Google Scholar
• Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2018;43(5):1742–1751.
   Web of Science ®Google Scholar
• Lugogo N, Domingo C, Chanez P, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a Multi-Center, Open-Label, Phase IIIb Study. Clin Ther. 2016;38(9):2058–2070. doi:10.1016/j.clinthera.2016.07.010
   PubMed Web of Science ®Google Scholar
• Gupta A, Pouliquen I, Austin D, et al. Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. Pediatr Pulmonol. 2019;54(12):1957–1967. doi:10.1002/ppul.24508
   PubMed Web of Science ®Google Scholar
• Henriksen DP, Bodtger U, Sidenius K, et al. Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma—a systematic review and meta-analysis. Eur Clin Respir J. 2018;5(1):1536097. doi:10.1080/20018525.2018.1536097
   PubMed Web of Science ®Google Scholar
• Pediatric postmarketing pharmacovigilance review: cinqair® (Reslizumab). [homepage on the Internet]. Available from: https://www.fda.gov/media/114068/download. Accessed April 27, 2021.
   Google Scholar
• Cooper K, Frampton G, Harris P, et al. Reslizumab for treating asthma with elevated blood eosinophils inadequately controlled by inhaled corticosteroids: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2018;36(5):545–553. doi:10.1007/s40273-017-0608-z
   PubMed Web of Science ®Google Scholar
• Teva. Cinqair (reslizumab) prescribing information. [homepage on the Internet]. Available from: https://hcp.cinqair.com/dosage-and-administration.aspx. Accessed April 27, 2021.
   Google Scholar
• Bateman ED, Djukanović R, Castro M, et al. Predicting responders to reslizumab after 16 weeks of treatment using an algorithm derived from clinical studies of severe eosinophilic asthma patients. Am J Respir Crit Care Med. 2019;199(4):489–495. doi:10.1164/rccm.201708-1668OC
   Web of Science ®Google Scholar
• Corren J, Weinstein S, Janka L, et al. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150(4):799–810. doi:10.1016/j.chest.2016.03.018
   PubMed Web of Science ®Google Scholar
• Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a Randomized Phase 3 Study. Chest. 2016;150(4):789–798. doi:10.1016/j.chest.2016.03.032
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. doi:10.1016/S2213-2600(15)00042-9
   PubMed Web of Science ®Google Scholar
• Brusselle G, Germinaro M, Weiss S, et al. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils. Pulm Pharmacol Ther. 2017;43:39–45. doi:10.1016/j.pupt.2017.01.011
   PubMed Web of Science ®Google Scholar
• Chanez P, McDonald M, Garin M, et al. Early decreases in blood eosinophil levels with reslizumab. J Allergy Clin Immunol. 2019;143(4):1653–1655. doi:10.1016/j.jaci.2018.12.997
   Web of Science ®Google Scholar
• Murphy K, Jacobs J, Bjermer L, et al. Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma. J Allergy Clin Immunol Pract. 2017;5(6):1572–1581. doi:10.1016/j.jaip.2017.08.024
   PubMed Web of Science ®Google Scholar
• Mukherjee M, Aleman Paramo F, Kjarsgaard M, et al. Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab. Am J Respir Crit Care Med. 2018;197(1):38–46. doi:10.1164/rccm.201707-1323OC
   PubMed Web of Science ®Google Scholar
• Sridhar S, Liu H, Pham TH, et al. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases. Respir Res. 2019;20(1):14. doi:10.1186/s12931-018-0968-8
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Fasenra® (benralizumab) prescribing information. [homepage on the Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf. Accessed February 22, 2021.
   Google Scholar
• AstraZeneca. Fasenra (benralizumb). Summary of product characteristics. [homepage on the Internet]. Available from: http://ec.europa.eu/health/documents/communityregister/2018/20180108139598/anx_139598_en.pdf. Accessed April 27, 2021.
   Google Scholar
• Bagnasco D, Caminati M, Ferrando M, et al. Anti-IL-5 and IL-5Ra: efficacy and safety of new therapeutic strategies in severe uncontrolled asthma. Biomed Res Int. 2018;2018:5698212. doi:10.1155/2018/5698212
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Wechsler ME, Fitzgerald JM, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. Eur Respir J. 2018;52(4):1800936. doi:10.1183/13993003.00936-2018
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Rinaldi B, et al. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma. Expert Opin Drug Metab Toxicol. 2017;13(9):1007–1013. doi:10.1080/17425255.2017.1359253
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Fitzgerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled cor-ticosteroids and long-acting β(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi:10.1016/S0140-6736(16)31324-1
   PubMed Web of Science ®Google Scholar
• Fitzgerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi:10.1016/S0140-6736(16)31322-8
   PubMed Web of Science ®Google Scholar
• Busse WW, Bleecker ER, Fitzgerald JM, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7(1):46–59. doi:10.1016/S2213-2600(18)30406-5
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–2458. doi:10.1056/NEJMoa1703501
   PubMed Web of Science ®Google Scholar
• Santini G, Mores N, Malerba M, et al. Dupilumab for the treatment of asthma. Expert Opin Investig Drugs. 2017;26(3):357–366. doi:10.1080/13543784.2017.1282458
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Dupilumab prescribing information. [homepage on the Internet]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761055s014lbl.pdf. Accessed February 22, 2021.
   Google Scholar
• European Medicines Agency. Dupilumab summary of product characteristics. [homepage on the Internet]. Available from: https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf. Accessed February 22, 2021.
   Google Scholar
• Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44. doi:10.1016/S0140-6736(16)30307-5
   PubMed Web of Science ®Google Scholar
• Busse WW, Maspero JF, Rabe KF, et al. Liberty asthma QUEST: phase 3 randomized, double-blind, placebo-controlled, parallel-group study to evaluate dupilumab efficacy/safety in patients with uncontrolled, moderate-to-severe asthma. Adv Ther. 2018;35(5):737–748. doi:10.1007/s12325-018-0702-4
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–2485. doi:10.1056/NEJMoa1804093
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. doi:10.1056/NEJMoa1804092
   PubMed Web of Science ®Google Scholar
• Maspero J, Fitzgerald M, Pavord I, et al. Dupilumab reduces severe exacerbation rate and improves lung function in adolescent patients with uncontrolled, moderate-to-severe asthma: from the Liberty Asthma Quest Study. Chest. 2018;154(4 Suppl):25A–27A. doi:10.1016/j.chest.2018.08.022
   Web of Science ®Google Scholar
• Sanofi. Evaluation of dupilumab in patients with persistent asthma (Liberty asthma quest). [homepage on the Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT02414854. NLM identifier: NCT02414854. Accessed February 22, 2021.
   Google Scholar
• Sanofi. Evaluation of dupilumab in patients with severe steroid dependent asthma (VENTURE). [homepage on the Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT02528214. NLM identifier: NCT02528214. Accessed February 22, 2021.
   Google Scholar
• Eyerich S, Metz M, Bossios A, et al. New biological treatments for asthma and skin allergies. Allergy. 2020;75(3):546–560. doi:10.1111/all.14027
   PubMed Web of Science ®Google Scholar
• Chan R, RuiWen Kuo C, Lipworth B, et al. Pragmatic clinical perspective on biologics for severe refractory type 2 asthma. J Allergy Clin Immunol Pract. 2020;8(10):3363–3370. doi:10.1016/j.jaip.2020.06.048
   PubMed Web of Science ®Google Scholar
• Ortega H, Llanos JP, Lafeuille MH, et al. Effects of systemic corticosteroids on blood eosinophil counts in asthma: real-world data. J Asthma. 2019;56(8):808–815. doi:10.1080/02770903.2018.1502301
   PubMed Web of Science ®Google Scholar
• Mukherjee M, Nair P. Blood or sputum eosinophils to guide asthma therapy? Lancet Respir Med. 2015;3(11):824–825. doi:10.1016/S2213-2600(15)00419-1
   PubMed Web of Science ®Google Scholar